Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 13,628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Actinic Keratosis
Interventions: Photodynamic therapy (PDT), Vitamin D3; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Phototoxicity
Interventions: MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation; Drug
Lead sponsor: MC2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Breast Cancer
Interventions: MIRA device imaging; Device
Lead sponsor: Real Imaging Ltd.; Industry
Eligibility: 30 Years to 70 Years · Female only
Enrollment: 740 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Cutaneous Lichen Planus
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Conditions: Breast Neoplasms
Interventions: Tamoxifen, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 4,740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Green Valley, Arizona • Green Velley, Arizona + 36 more

Conditions: Skin Laxity, Wrinkles
Interventions: Not listed
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 25 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Melanoma
Interventions: PV-10, Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Vasculitis, Wegener's Granulomatosis
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alopecia
Interventions: Paxman Scalp Cooling Device; Device
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Breast Carcinoma, Head and Neck Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
Interventions: Electronic Health Record Review, Medical Device Usage and Evaluation, Survey Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cutaneous Lupus Erythematosus (CLE)
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Breast Cancer
Interventions: Cisplatin, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 15
States / cities: Aurora, Colorado • Derby, Connecticut • Guilford, Connecticut + 9 more

Conditions: Metastatic Breast Cancer
Interventions: docetaxel, capecitabine; Drug
Lead sponsor: Cancer Research Network; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Patient Positioning, Monitoring, Physiologic, Pressure Ulcer
Interventions: Zephyr BioPatch; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Vaginitis, Dyspareunia, Breast Neoplasms
Interventions: Testosterone propionate; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Burlington, Vermont

Conditions: Breast Cancer, Hot Flashes
Interventions: informational intervention; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: filgrastim, cyclosporine, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody m170, yttrium Y 90 monoclonal antibody m170; Biological · Drug · Procedure + 1 more
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
Interventions: CDX1307; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina

Conditions: Genital Warts
Interventions: 2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more

Conditions: Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Interventions: Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions: Sparsentan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more

Conditions: Malignant Melanoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more

Conditions: Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more

Conditions: Hidradenitis Suppurativa
Interventions: AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose; Drug
Lead sponsor: IntegoGen, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

A Retrospective Study to Evaluate the Effectiveness of the Ulthera System

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes

Hair Loss Prevention Study for Pancreatic Cancer

Evaluating Patient Reported Outcomes in Radiation Therapy, the PRO-RT Study

Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer

An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa